Viking Therapeutics Plunges 44% On Mixed Phase 2 Obesity Trial Results
Viking Therapeutics, Inc. (VKTX) fell 43.72%, dragging down the PRISM Emerging Weight Loss Index, after investors reacted sharply to Phase 2 trial data on its oral obesity drug VK2735. While patients on VK2735 lost 12.2% of body weight in just 13 weeks compared with 1.3% for placebo, the trial revealed a 28% patient dropout rate, largely due to gastrointestinal side effects including nausea and vomiting. Analysts noted the results appear inferior to Eli Lilly’s oral GLP-1/GIP candidate, orforglipron, which delivered similar weight loss over a much longer 72-week trial with a lower discontinuation rate. Viking emphasized that most adverse events were mild, but the high dropout figure raised concerns about long-term tolerability and competitive positioning.
Kandi Technologies Gains 17% on Margin Expansion and Strategic Moves
Kandi Technologies Group, Inc. (KNDI) rose 17.13%, lifting the PRISM Emerging EV Index, after posting first-half 2025 financial results that showed significant margin improvements despite revenue pressure. Gross margin expanded to 45.2% from 31.7% last year, supported by product mix optimization and regional sales strength. Net income came in at $1.7M, down from $2.4M, but the company maintained a robust cash position of $256.7M. Management highlighted strategic partnerships in embodied intelligence robotics and battery swap infrastructure, including a deal under CATL’s “Ten Thousand Station Plan.”
Other PRISM Mid-Day Movers:
• Catheter Precision, Inc. (VTAK) down 24.00%
• Energy Fuels Inc. (UUUU) down 17.59%
The post PRISM Mid-Day Movers: Weight Loss Data Sparks Selloff While EV Margins Impress appeared first on PRISM MarketView.
